Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry
Allergy2019Vol. 75(1), pp. 116–126
Citations Over TimeTop 1% of 2019 papers
Lieneke F.M. Ariëns, Jorien van der Schaft, Daphne S. Bakker, Deepak M.W. Balak, Margreet L. E. Romeijn, T. Kouwenhoven, Marijke Kamsteeg, Barbara Giovannone, Julia Drylewicz, Cynthia C. A. van Amerongen, Evelien M. Delemarre, Edward F. Knol, Femke van Wijk, Stefan Nierkens, Judith L. Thijs, Marie L. A. Schuttelaar, Marjolein de Bruin‐Weller
Abstract
Treatment with dupilumab significantly improved disease severity and decreased severity-related serum biomarkers in patients with very difficult-to-treat AD in a daily practice setting.
Related Papers
- → Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis(2023)11 cited
- → Multicenter Canadian case series of pediatric patients less than 12 years of age with moderate‐to‐severe atopic dermatitis treated with dupilumab(2023)9 cited
- → Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial(2018)4 cited
- Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK.(2021)